Core Viewpoint - The China Securities Regulatory Commission (CSRC) has introduced measures to support unprofitable technology companies with key core technologies and market potential to list on the Sci-Tech Innovation Board, enhancing the inclusiveness of the system [1] Group 1: Company Overview - Angrui Microelectronics is focused on integrated circuit design in the RF and analog fields, developing RF front-end chips for smart mobile terminals and RF SoC chips for IoT applications [4] - The company has achieved significant sales with its RF front-end chips across major smartphone brands, excluding Apple, and has established partnerships with industrial and medical clients [4] Group 2: Financial Performance - Angrui Microelectronics has reported cumulative losses exceeding 800 million yuan over the past three years, with plans to raise 2.067 billion yuan through its IPO for R&D and industrial upgrades [5] - The company’s revenue has shown a compound annual growth rate of approximately 50.88%, with revenues of 923 million yuan, 1.695 billion yuan, and 2.101 billion yuan for 2022, 2023, and 2024 respectively [6] - Despite increasing revenues, the company has continued to incur losses, with net profits of -290 million yuan, -450 million yuan, and -64.71 million yuan over the same period [6][8] Group 3: Financial Metrics - The total assets of Angrui Microelectronics reached approximately 1.721 billion yuan in 2024, with a debt-to-asset ratio of 43.22%, up from 17.71% in 2022 [7][10] - The company’s gross profit margin has gradually increased to 20.22% in 2024, although it remains below the industry average of 25.83% [8][9] - Operating cash flow has been negative, indicating ongoing financial strain, with net cash flows from operating activities of -394.56 million yuan, -670.91 million yuan, and -1.867 billion yuan over the past three years [10][12] Group 4: Ownership and Control Issues - The founder, Yang Qinghua, unexpectedly left the company during its push for financing and listing, raising questions about the company's governance [3][16] - The current actual controller, Qian Yongxue, acquired control through loans, and the first major shareholder, Beijing Xinke, faces risks related to a partner involved in illegal fundraising [3][20] - The complex ownership structure and the potential legal issues surrounding a limited partner could pose significant challenges for Angrui Microelectronics in its IPO process [20][22]

Core Viewpoint - The Shanghai Stock Exchange has scheduled a listing review meeting for Shenzhen Beixin Life Technology Co., Ltd. on July 18, 2025, marking a significant step in the company's IPO process after previous attempts to list on the Hong Kong Stock Exchange failed [1][3]. Group 1: Company Overview - Beixin Life is a medical device company that previously attempted to list on the Hong Kong Stock Exchange but faced setbacks, including an expired prospectus [3]. - The company signed a listing guidance agreement with China International Capital Corporation in October 2022, aiming for a listing on the STAR Market [3]. - Beixin Life's updated prospectus indicates a revised fundraising target of 9.52 billion yuan, down from an initial 12.74 billion yuan [3]. Group 2: Fundraising and Project Allocation - The total investment for the company's projects is approximately 127.39 million yuan, with significant allocations for the construction of an interventional medical device industrialization base and R&D projects [4]. - The updated prospectus shows a reduction in the proposed fundraising for the interventional medical device R&D project from 3.76 billion yuan to 2.82 billion yuan, reflecting a decrease of about 937 million yuan [6]. Group 3: Production Capacity and Utilization - Beixin Life's IVUS system capacity utilization rates have improved significantly, reaching 98.64% in 2024, while the FFR system's utilization was 67.54% [7][8]. - The company anticipates that the industrialization base project will achieve stable production by 2030, with projected annual capacities of 545,000 units for IVUS and 360,000 units for FFR [9]. Group 4: Financial Performance - Beixin Life reported revenues of approximately 92.45 million yuan, 184 million yuan, and 317 million yuan for 2022, 2023, and 2024, respectively, with net losses decreasing from 300 million yuan in 2022 to 53.74 million yuan in 2024 [10][11]. - The company's R&D expenses have decreased over the years, with a notable drop in the R&D expense ratio from 154.95% in 2022 to 35.65% in 2024 [12]. Group 5: Shareholder Dynamics - Several shareholders have exited the company prior to its application for listing on the STAR Market, with notable transactions involving SpringHill and Shihezi Taiyu [17][18]. - The company has undergone multiple rounds of financing, with commitments made by investors that included performance-based clauses related to the company's IPO timeline [17].

Core Viewpoint - Xiamen Hengkang New Materials Technology Co., Ltd. (referred to as "Hengkang New Materials") has responded to the second round of inquiry from the Shanghai Stock Exchange, addressing seven categories of questions including customer concentration, revenue, inventory, R&D, fundraising projects, and production land [1][3]. Customer Concentration and Revenue - Hengkang New Materials is the largest supplier of photoresist materials to customer A1, with sales revenue from SKMP's introduced photoresist materials amounting to approximately 138 million yuan, 116 million yuan, and 142 million yuan for 2022, 2023, and 2024 respectively [1][3]. - The company reported a significant decline in orders from customer A1, with on-hand orders decreasing from 47.51 million yuan to 17.73 million yuan over the reporting periods [3]. - As of June 2025, the total on-hand orders from customer A1 were 158 million yuan, reflecting a drop compared to previous periods due to fluctuating order cycles [4]. Financial Performance - In the first half of 2025, Hengkang New Materials generated approximately 288 million yuan in revenue, a 22.68% increase from 235 million yuan in the same period of 2024. Self-produced product revenue rose by 72.53% to 250 million yuan, while introduced product revenue fell by 57.40% to approximately 38.37 million yuan [4][5]. - The overall gross profit for the first half of 2025 was reported at 116.5 million yuan, down 9.99% from the previous year [5]. R&D and Product Development - The company has established a self-research and development strategy for photoresist materials since 2020, focusing on domestic production to meet customer demands [3][6]. - Hengkang New Materials is collaborating with Xiamen University to enhance its R&D capabilities, focusing on key materials for advanced integrated circuit manufacturing [6]. Fundraising and Project Adjustments - Hengkang New Materials initially planned to raise 1.2 billion yuan for various projects but has since revised its fundraising target to 1.007 billion yuan, dropping the SiARC development and industrialization project from its fundraising agenda [6][7]. - The Shanghai Stock Exchange has requested detailed explanations regarding the necessity and rationality of the adjusted fundraising projects, including land use and potential risks of excess capacity [7].

Core Insights - A total of 51 new companies were listed on the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Beijing Stock Exchange from January to June 2025, raising a total of 37.3 billion yuan [1] - Among these, 7 companies were listed on the Sci-Tech Innovation Board, collectively raising 5.619 billion yuan [1] Listing Details - The 7 companies that chose the first set of listing standards include: - Ying Shi Innovation (688775.SH) listed on June 11, 2025, raising 1.93807 billion yuan with underwriting fees of 158.3475 million yuan [1] - Han Bang Technology (688755.SH) listed on May 16, 2025, raising 500.94 million yuan with underwriting fees of 37.2891 million yuan [1] - Sheng Ke Nano (688757.SH) listed on March 25, 2025, raising 366.21 million yuan with underwriting fees of 43.9448 million yuan [1] - Hai Bo Si Chuang (688411.SH) listed on January 27, 2025, raising 861.1 million yuan with underwriting fees of 66.4722 million yuan [1] - Xing Fu Electronics (688545.SH) listed on January 22, 2025, raising 1.168 billion yuan with underwriting fees of 82.0755 million yuan [1] - Si Kan Technology (688583.SH) listed on January 15, 2025, raising 568.82 million yuan with underwriting fees of 46.0744 million yuan [1] - Sai Fen Technology (688758.SH) listed on January 10, 2025, raising 215.89 million yuan with underwriting fees of 25.283 million yuan [1] Listing Standards - The listing standards for the Sci-Tech Innovation Board require either: - An expected market value of no less than 1 billion yuan, positive net profits for the last two years, and a cumulative net profit of no less than 50 million yuan, or - An expected market value of no less than 1 billion yuan, positive net profit for the last year, and operating revenue of no less than 100 million yuan [1]

Core Viewpoint - Beijing Yitang Semiconductor Technology Co., Ltd. is set to conduct an initial public offering (IPO) and list on the Sci-Tech Innovation Board, following the approval from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][6]. Group 1: IPO Details - The IPO will involve a combination of strategic placement, offline issuance, and online issuance [2][7]. - The stock will be named "Yitang Co., Ltd." with the stock code "688729" for the IPO and "787729" for online subscription [6]. - The initial inquiry period for the IPO is scheduled for June 24, 2025, with a price range of 7.11 to 8.80 yuan per share [7][8]. Group 2: Underwriters - Guotai Junan Securities Co., Ltd. and China International Capital Corporation are the joint lead underwriters for this IPO [2][9]. - The underwriters will manage the strategic placement and the inquiry process for offline and online subscriptions [2]. Group 3: Investor Participation - A total of 247 offline investors submitted 6,203 inquiries, with a total proposed subscription of 38,429,590 shares [7]. - After excluding invalid bids, 6,159 valid bids remained, with a total proposed subscription of 38,214,000 shares [8].

保荐人（联席主承销商）：中信证券股份有限公司 联席主承销商：高盛（中国）证券有限责任公司 联席主承销商：中国国际金融股份有限公司 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，影石创新科技股份有限公司（以下简称"影石 创新"、"公司"、"本公司"或"发行人"）发行的人民币普通股股票将于 2025 年 6 月 11 日在上海证券交易所科创板上市，上市公告书全文和首次公开发行股 票的招股说明书在上海证券交易所网站（http://www.sse.com.cn/）和符合中国证 监会规定条件网站（上海证券报：https://www.cnstock.com；中国证券报： https://www.cs.com.cn/ ；证券日报： http://www.zqrb.cn ；证券时报： https://www.stcn.com ； 经 济 参 考 报 ： http://www.jjckb.cn ； 中 国 日 报 ： https://cn.chinadaily.com.cn；金融时报：https://www ...

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. has successfully completed its initial public offering (IPO) and is now listed on the Sci-Tech Innovation Board, with the stock code "688755" [1][2]. Group 1: IPO Details - The IPO price was set at 22.77 yuan per share, with a total issuance of 22 million shares, all of which are new shares [2]. - The initial strategic placement was 4.4 million shares, accounting for 20% of the total issuance, with no need for a downward adjustment to the offline allocation [2][3]. - The final allocation after the strategic placement resulted in 10.56 million shares for offline issuance (60%) and 7.04 million shares for online issuance (40%) [3]. Group 2: Subscription and Allocation - The online subscription saw an effective multiple of approximately 4,442.92 times, prompting the activation of a reallocation mechanism [3]. - The final online issuance had a winning rate of 0.03001029% after the reallocation [3]. - The strategic placement included various investors, such as subsidiaries of CITIC Securities and large insurance companies with long-term investment intentions [4][5]. Group 3: Underwriting and Fees - CITIC Securities acted as the lead underwriter, with a total of 30,971 shares being underwritten, representing about 0.176% of the final issuance [6]. - The underwriting fees are structured to be paid in stages based on the project's progress, with all fees excluding VAT [7].

中邮科技股份有限公司 首次公开发行股票并在科创板上市 发行安排及初步询价公告 联席保荐人（联席主承销商）：中国国际金融股份有限公司 联席保荐人（联席主承销商）：中邮证券有限责任公司 重要提示 中邮科技股份有限公司（以下简称"中邮科技"、"发行人"或"公司"） 根据中国证券监督管理委员会（以下简称"中国证监会"或"证监会"）颁布的 《证券发行与承销管理办法》（证监会令〔第 208 号〕）（以下简称"《管理办法》"）、 《首次公开发行股票注册管理办法》（证监会令〔第 205 号〕），上海证券交易所 （以下简称"上交所"）颁布的《上海证券交易所首次公开发行证券发行与承销 业务实施细则》（上证发〔2023〕33 号）（以下简称"《业务实施细则》"）、《上 海市场首次公开发行股票网上发行实施细则（2023 年修订）》（上证发〔2023〕35 号）（以下简称"《网上发行实施细则》"）、《上海市场首次公开发行股票网下 发行实施细则（2023 年修订）》（上证发〔2023〕36 号）（以下简称"《网下发行 实施细则》"），中国证券业协会颁布的《首次公开发行证券承销业务规则》（中 证协发〔2023〕18 号）（以下简称"《承销 ...

上海阿拉丁生化科技股份有限公司 首次公开发行股票并在科创板上市 发行公告 保荐机构（主承销商）：西部证券股份有限公司 特别提示 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"、"发行人"或"公司"） 根据中国证券监督管理委员会（以下简称"中国证监会"）颁布的《关于在上海证 券交易所设立科创板并试点注册制的实施意见》（证监会公告〔2019〕2 号）、《证 券发行与承销管理办法》（证监会令〔第 144 号〕）（以下简称"《管理办法》"）、 《科创板首次公开发行股票注册管理办法（试行）》（证监会令〔第 153 号〕），上 海证券交易所（以下简称"上交所"）颁布的《上海证券交易所科创板股票发行与 承销实施办法》（上证发〔2019〕21 号）（以下简称"《实施办法》"）、《上海证券 交易所科创板股票发行与承销业务指引》（上证发〔2019〕46 号）（以下简称"《业 务指引》"）、《上海市场首次公开发行股票网上发行实施细则》（上证发〔2018〕 40 号）（以下简称"《网上发行实施细则》"）、《上海市场首次公开发行股票网下 发行实施细则》（上证发〔2018〕41 号）（以下简称"《网下发行实施细则》"）， 中国证券业 ...

吉林省中研高分子材料股份有限公司 首次公开发行股票科创板 上市公告书提示性公告 保荐人（主承销商）：海通证券股份有限公司 一、上市概况 （五）首次公开发行股份数量：30,420,000 股（本次发行全部为新股，无老 股转让） 二、风险提示 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市初 期的投资风险，提醒投资者充分了解交易风险、理性参与新股交易，具体如下： （一）涨跌幅限制放宽带来的股票交易风险 1 （一）股票简称：中研股份 （二）扩位简称：中研股份 （三）股票代码：688716 （四）首次公开发行后总股本：121,680,000 股 扫描二维码查阅公告全文 本公司及全体董事、监事、高级管理人员保证信息披露的内容真实、准确、 完整、及时，没有虚假记载、误导性陈述或重大遗漏。 经上海证券交易所审核同意，吉林省中研高分子材料股份有限公司（以下简 称"本公司"）发行的人民币普通股股票将于 2023 年 9 月 20 日在上海证券交易所 科创板上市，上市公告书全文和首次公开发行股票的招股说明书全文在上海证券 交易所网站（http://www.sse.com.cn/）和符合中国证监会规定条件网站（中 ...